US DTRA contracts PsiOxus for biodefence vaccine adjuvants development
The US Defense Threat Reduction Agency (DTRA) has contracted PsiOxus Therapeutics for development of biodefence vaccine adjuvants, to improve safety and efficacy of two vaccines.